权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development and validation of a law-cost cerebral oximeter for detection of cognitive impairment and Alzheimer's disease

用于检测认知障碍和阿尔茨海默病的低成本脑血氧计的开发和验证

基本信息

批准号：
10214169
负责人：
Maria Angela Franceschini
金额：
$ 46.2万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-05-01 至 2024-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10214169
关键词：
Acute Age Aging Alzheimer&apos s Disease Alzheimer&apos s disease diagnosis Alzheimer&apos s disease pathology Alzheimer&apos s disease risk Amyloid Area Behavioral Benign Blood Vessels Bluetooth Brain Cardiovascular system Cerebrovascular Circulation Cerebrovascular Disorders Cerebrovascular Physiology Cerebrovascular Trauma Cerebrum Clinical Clinical Research Cognitive Cognitive aging Communities Complement Computer software Dependence Detection Deterioration Development Devices Disease Elderly Etiology Evaluation Event Frequencies Future Goals Gold Health Heart Heart Rate Hemoglobin Heterogeneity Impaired cognition Impairment Individual Intervention Laws Lesion Link Magnetic Resonance Imaging Measurement Measures Methods Monitor Near-Infrared Spectroscopy Nerve Degeneration Neurobehavioral Manifestations Neurodegenerative Disorders Pathologic Pathology Patients Performance Pharmacology Physiological Physiology Predictive Factor Prevention Primary Health Care Production Property Research Risk Signal Transduction Stroke Technology Testing Therapeutic Time Tissues Translating Validation Vascular Dementia Vascular Diseases White Matter Hyperintensity Wireless Technology Work attenuation brain tissue cerebrovascular cerebrovascular health cerebrovascular pathology clinical Diagnosis clinical care clinical practice clinically significant cognitive capacity cost data streams design flexibility handheld mobile device high standard indexing interest lifestyle factors medical specialties medically underserved population mild cognitive impairment neurocognitive disorder neuroimaging neurovascular novel prevent prototype relating to nervous system screening sensor signal processing socioeconomics tau Proteins tissue injury tissue oxygenation vascular cognitive impairment and dementia web interface white matter

项目摘要

Project Summary/Abstract. It is now understood that cerebrovascular dysfunction contributes to a host of neurocognitive disorders including the reduction in cognitive capacity with typical aging as well as the more serious impairments resulting from vascular disease and dementia. Cerebrovascular pathology is also highly prevalent in patients with Alzheimer’s disease (AD) and is an important factor contributing to the conversion from an independent state of mild cognitive impairment to the functional dependence associated with Alzheimer’s dementia. Thus, vascular health and disease are important mechanisms contributing to heterogeneity in cognitive aging and progression to vascular and Alzheimer’s dementias. Unlike the proteinopathies of AD and other neurodegenerative conditions, vascular health is immediately modifiable through behavioral and lifestyle factors, as well as a range of pharmacological and device related interventions. Thus, it is critical to develop methods for quantitative tracking of metrics of cerebrovascular health that could be used to detect the earliest stages of abnormalities that may require intervention. Optimally, such technology would be wireless, mobile/web interfacing and would be very low cost allowing for accessibility to traditionally medically underserved populations. We have designed and prototyped such a device that would permit widespread cerebrovascular monitoring in older adults. The goal of this R21 proposal is to complete the development of, and to validate this novel low-cost cerebral oximeter that can be used to screen for cerebrovascular disorders that contribute to cognitive impairment and increase risk for the development of AD. To do so, we will aim to Specific Aim 1: 1a) complete the design and casing and programming of our existing developed device; 1b) to optimize the design for high performance and reliable physiological signal detection; Aim 2: 2a) to validate performance of the low-cost mobile oximeter relative to gold standard high grade cerebral oximeter; 2b) to validate performance of the low-cost mobile oximeter relative to cerebral physiology measurements obtained by magnetic resonance imaging. The proposed sensor would promote widespread cerebrovascular monitoring in individuals at risk for vascular dysfunction and neurocognitive disorders. Ultimately, in the future, we aim for this sensor to be translated for use in clinical practice for generalized primary care as well as specialty clinical use.

项目概要/摘要。现在已经知道脑血管功能障碍是导致许多神经认知障碍的原因包括认知能力的下降以及更严重的损伤由血管疾病和痴呆症引起。脑血管病变在患者中也非常普遍阿尔茨海默病（AD），是一个重要因素，有助于从一个独立的转换从轻度认知障碍状态到与阿尔茨海默氏痴呆症相关的功能依赖。因此，在本发明中，血管健康和疾病是导致认知老化异质性的重要机制，发展成血管性痴呆和阿尔茨海默氏痴呆与AD和其他蛋白质病不同，在神经退行性疾病中，血管健康可以通过行为和生活方式立即改变因素，以及一系列药理学和器械相关干预。因此，开发用于定量跟踪脑血管健康指标的方法，可用于检测最早的可能需要干预的异常阶段。最理想的情况是，这种技术将是无线的，移动的/网络接口，并且将是非常低的成本，允许传统医学的可访问性。服务不足的人群。我们已经设计并制作了这样一种设备的原型，老年人的脑血管监测。本R21提案的目标是完成以下方面的开发，并验证这种新型低成本脑血氧仪可用于筛查脑血管疾病导致认知障碍并增加AD发展风险。为此，我们将致力于具体目标1：1a）完成我们现有开发设备的设计、封装和编程; 1b）优化设计，实现高性能和可靠的生理信号检测;目标2：2a）验证低成本移动的血氧计相对于金标准高级脑血氧计的性能; 2b）确认低成本移动的血氧计相对于获得的脑生理测量值的性能通过磁共振成像。拟议的传感器将促进广泛的脑血管监测在有血管功能障碍和神经认知障碍风险的个体中。最终，我们的目标是，该传感器将被转换用于临床实践，用于一般初级护理以及专业临床使用.